What is the beginning dose of Wegovy, and why does it start so low?

Why does the Wegovy dose begin so low, is 0.25mg actually doing anything?

A question our prescribers hear most weeks is some version of this: "I've been on it for a month and nothing's happened, am I on the wrong dose?" The honest answer is that 0.25mg is not designed to produce significant weight loss on its own. It is there to prepare your digestive system for the doses that follow.

Semaglutide works by activating GLP-1 receptors, which slows the rate at which the stomach empties and increases feelings of fullness after meals. At therapeutic levels, those effects are strong enough to cause real nausea, vomiting and disrupted digestion in many people. Starting low gives the body time to adapt before the dose climbs to a level where the appetite effects become meaningful. The full Wegovy dosing schedule explains each step in detail, but the logic of the opener is simple: a slower start means most people can reach the maintenance dose without dropping out due to side effects.

Evidence from the STEP 1 trial, published in the New England Journal of Medicine, showed an average body weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. That outcome depends on people being able to reach and sustain 2.4mg, which the staged titration makes more likely.

What does the full titration path look like from the first pen?

After the opening month at 0.25mg, the prescriber typically moves treatment to 0.5mg for four weeks, then 1.0mg, then 1.7mg, arriving at 2.4mg around week 17. Some people need a longer stretch at one level, if side effects at a particular step are troublesome, a prescriber may recommend holding there for an extra month before going up. That decision always belongs to the prescriber, not to the patient alone.

Since April 2026 there has also been a 7.2mg option, following MHRA approval of a dedicated single-dose pen. This higher ceiling is for adults with a BMI of 30 or above and is not a starting point, it is the highest rung of an already lengthy ladder. The guide to Wegovy pen doses covers the specific pen formats available at each stage.

One practical thing to keep in mind: each dose increase tends to bring a brief return of GI symptoms. The nausea or loose stools that faded after week one of 0.25mg may reappear briefly when you move to 0.5mg. This is normal and generally resolves within a few days to two weeks, as the NHS semaglutide page confirms. Eating smaller meals, avoiding high-fat foods and staying well hydrated all help during that adjustment window.

Does the beginning dose affect how much weight you lose overall?

Not directly, no. The 0.25mg phase has little measurable effect on appetite or weight for most people. What it does affect is whether someone reaches the maintenance dose at all. Clinical trials that showed meaningful average weight loss enrolled participants through the same gradual titration, the 15% average in STEP 1 reflects outcomes across the entire 68-week period, including those early weeks.

Where the starter period does matter is attention to what you do alongside treatment. Appetite suppression at the beginning is mild, so the early weeks are a useful time to build the habits (protein-focused meals, regular movement, adequate sleep) that make the maintenance phase more effective. Waiting until 2.4mg to think about those things means missing a low-pressure window.

It is also worth knowing that for some people, progress stalls or weight creeps back before the maintenance dose is reached. Gaining weight while titrating is more common than often discussed and does not necessarily mean the medicine is not working.

Who decides whether the dose increases, and when?

The titration is always a prescriber decision, reviewed at each stage. At nume, every repeat order is clinically re-assessed, a named prescriber reads your update before any dose change is approved. That review looks at how you have tolerated the current dose, whether your weight is responding as expected, and whether anything in your health picture has changed.

The starting eligibility for Wegovy is a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is never the only consideration, the prescriber's full assessment is what determines suitability. If you are thinking about whether treatment could be right for you, starting a free consultation is the straightforward next step. There is no commitment, and the review happens the same day.

Cost is a fair question too, and Wegovy pricing in the UK covers what a private prescription typically includes and how to read a quote sensibly.